Lifecare ASA

Lifecare ASA: Share capital increase and warrants registered

Reference is made to the stock exchange announcement published by Lifecare ASA

("Lifecare" or the "Company") on 14 June 2024 regarding the final results of

the partially underwritten rights issue of new shares in the Company (the

"Rights Issue").

The share capital increase pertaining to the issuance of 59,038,955 new shares

in the Rights Issue has now been registered with the Norwegian Register of

Business Enterprises. The Company's new share capital is NOK 77,561,878.80

divided on 193,904,697 shares, each with a par value of NOK 0.40.

The subscribers in the Rights Issue were allocated one warrant for every two

shares allocated to, and paid by, them in the Rights Issue (the "Warrants").

Further, Munkekullen 5 Förvaltning AB and Buntel AB, having underwritten a

total of NOK 50 million of the Rights Issue, were allocated a total of

25,000,000 warrants at equal terms to the Warrants, as compensation for their

underwriting commitment (the "Additional Warrants"). The issuance of in total

29,519,478 Warrants and 25,000,000 Additional Warrants has now been registered

with the Norwegian Register of Business Enterprises.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-06-25 14:47 CEST.

AI Terminal